ASTRO 2017: Immune Markers in Prostate Cancer Predict RT Response
This video highlights a new study that found that markers of immune response in prostate cancer may be able to predict patients’ response to radiation therapy, likelihood of recurrence, and survival.
In this video, Shuang George Zhao, MD, MSE, of the University of Michigan in Ann Arbor, discusses a new study that analyzed more than 9,000 prostate tumors and found that markers of immune response may be able to predict prostate cancer patients’ response to radiation therapy, likelihood of recurrence, and survival. The study also found evidence that PD-L2 could be a therapeutic target in prostate cancer.
Zhao presented results of the study (abstract 3) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
